【10/19更新】そーせいグループ(株)【4565】は一体どこまで下がるのか。今後の値動きは？

>>318
だってマザーズ上がってるからそーせい買おうとかミクシー買おうってなる人いないしなｗ

proはマイネット大口抜け始めた日の4500近辺も完全オーバーシュートと言っていたし、イグニスの7000近辺、そーせいの2万円割れ、アジア開発の20割れ、Sサイエンスの200割れとか、とんでもない所でオーバーシュート連呼www
逆指標として使った方が儲かるが、制度信用銘柄が無いから、空売りが出来ないのが残念過ぎるww

本日乙
そーせいガチホ

そーせいきたああああああ

そーせいですら上げているというのに俺株主力陣の情けなさよ・・・

そーせいうわあああああああああああああああああ

そーせいまいてん

時価総額
サイバーダイン　2087億
パークシャー　　1723億
そーせいは抜いたけどサイバーダインも抜いちゃうのかな

>>455
ダインより有望な感じはするなしらんけど

GMOのアプリの銘柄検索で「串カツ」って検索すると何でそーせいが引っかかるの？串カツ屋なの？

本日乙
ちょこちょこ取引
そーせいガチホ

そーせいよりPKの方が時価総額デカイってｗｗｗ

ミクシィやサイバーダイン、そーせいは無風

そーせいマイテンんんんんんんんん

そーせいの出来高ｗｗｗ

そーせいは集めたまま終わりましたけどね

昔のそーせいも握ってればその内助かると思ってガチホしてた時期が俺にもありました…

そーせいは上でたんまり売り直されただけか

直近で外人が買ってたそーせいとサンバイオが売られるのは嫌な感じ

そーせいほんま

そーせいワロタあああああああああああああああああああああああああ

ミクシィとかそーせい強いよ

そーせいいったあああああ

キミらのそーせい売られてるで(´・ω・`)

そーせいミカン

そーせいみかんｗ

※Sunovion Announces Seebri™ Neohaler® (glycopyrrolate) Inhalation Powder is Now Available in the United States. (10/19)

– SEEBRI NEOHALER is a long-acting muscarinic antagonist (LAMA) for people with chronic obstructive pulmonary disease (COPD) -

Marlborough, Mass., October 19, 2017 –
Sunovion Pharmaceuticals Inc. (Sunovion) today announced that Seebri™ Neohaler® (glycopyrrolate) Inhalation Powder, 15.6 mcg twice daily, is now available at pharmacies in the United States for the long-term maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. SEEBRI NEOHALER is a long-acting muscarinic antagonist (LAMA).

Sunovion entered into an exclusive license agreement with Novartis for the U.S. commercialization rights to SEEBRI NEOHALER, as well as Utibron™ Neohaler® and Arcapta® Neohaler® , on December 21, 2016.
Novartis received approval from the U.S. Food and Drug Administration (FDA) for SEEBRI NEOHALER in October 2015.

“As a part of our commitment to millions of people living with COPD in the United States, Sunovion is pleased to introduce SEEBRI NEOHALER as a new treatment option,” said David Frawley, Executive Vice President and Chief Commercial Officer at Sunovion.
“SEEBRI NEOHALER, a handheld, dry powder inhaler, is an important part of Sunovion’s COPD portfolio that includes a broad range of medications and delivery methods that can address individual patient needs.”

In two multi-center, double-blind, placebo-controlled, parallel group randomized trials, SEEBRI NEOHALER demonstrated statistically significant improvements in change from baseline in lung function over 12 hours (FEV1 AUC 0-12h) compared to placebo (p<0.001).1,2 Improvements in lung function were also measured by forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) within five and 15 minutes post-dose versus placebo on Day 1 and Week 12.
Results showed reduced use of rescue medication and improvements in health-related quality of life, as measured by the St. George’s Respiratory Questionnaire (SGRQ) total score, which is a composite of patient-reported symptoms, activities and impact on daily living.

“COPD is a serious, progressive respiratory disease that should have a personalized approach to choosing a therapy and delivery method, and there remains a need for additional treatment options for newly diagnosed patients as well as those managing uncontrolled symptoms,” said Edward Kerwin, M.D., Medical Director of the Clinical Research Institute of Southern Oregon.
“SEEBRI NEOHALER is a long-acting muscarinic antagonist delivered through a small, handheld inhaler that provides important audiovisual feedback to patients, caregivers and health care providers.”

ちなみにURLな、これで上がったんなら寂しいよなあ。限定的。

h
ttp://www.businesswire.com/news/home/20171019005698/en/Sunovion-Announces-Seebri™-Neohaler®-glycopyrrolate-Inhalation-Powder

最近はそーせいの掲示板も退屈だな
ホルダーたちの投稿から夢みたいなものを感じ取ることができない
3年くらい前までは 失っても20万円だったが今は失うときは100万円だからな
ホルダーのみんながビクビクしながら少ない利ざやを取ることだけに集中しているのがよくわかる
ianのおっさんは信用玉を損切りする前は掲示板に連投するしさ

↓だからPTS下げてんのか。納得。

PTSで急に投げ売り出始めた、9800だよ

↓これで上がったんなら寂しいなあ。

BusinessWire
2017/10/19 8:11
Sunovion Announces Seebri™ Neohaler® (glycopyrrolate) Inhalation Powder is Now Available in the United States
– SEEBRI NEOHALER is a long-acting muscarinic antagonist (LAMA) for people with chronic obstructive pulmonary disease (COPD) –

☆★そーせいグループ(株) ＜明日の【決算】 速報（10月20日）＞
saw.anpmech.com

※Pluristem: "FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation Syndrome. (10/19)

Pluristem’s ARS program is developed and funded by the U.S. National Institutes of Health and the U.S. Department of Defense, and is in preparation for a pivotal study

HAIFA, Israel, Oct. 19, 2017 -- Pluristem Therapeutics Inc.,
a leading developer of placenta-based cell therapy products, announced today that the U.S. Food and Drug Administration (FDA) has granted the company an orphan drug designation for its PLX-R18 cell therapy for the prevention and treatment of acute radiation syndrome (ARS).

ARS results from exposure to high levels of radiation, such as in the case of a nuclear accident or attack, and can lead to severe health consequences including death. The Orphan Drug Act provides for granting special status to a drug or biological product, to treat a rare disease or condition.
The benefits of achieving Orphan Drug Designation include close guidance by the FDA, which may accelerate the path to potential marketing approval, orphan drug grants, tax credits, and 7-year market exclusivity upon marketing approval.

Pluristem recently reported positive data from non-human primates (NHPs) studies of PLX-R18 cells as a treatment for ARS conducted by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), U.S. Department of Health and Human Services (DHHS).
The reported data demonstrated improvement in survival rates of such NHPs and the enhancement of recovery across all three major blood lineages—white blood cells, red blood cells, and platelets.
In addition, PLX-R18 cells are also being studied by the U.S. Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute (AFRRI) to examine the effectiveness of the cells as a treatment for ARS prior to, and within the first 24 hours of exposure to radiation.
Pluristem PLX-R18 cells are also being studied by Fukushima Medical University in Japan for the treatment of ARS and as an adjunct to radiotherapy in cancer patients.

“Pluristem has a vast and dynamic program developing our PLX-R18 therapy as a treatment for ARS, which can potentially save many lives,” said Zami Aberman, Co-CEO and Chairman of Pluristem.
“Receiving Orphan Drug Designation brings us one step closer to providing a next-generation medical countermeasure against ARS, which is especially important given today’s volatile political climate.”

ダウ先物が急落してますね。
そろそろ日経平均連騰も終わりでしょう。

この日経連騰に全く関係なかった、そーせいに明日から資金が回ってきますよ。
希望的観測ですがね♪アハハ
(^^)